Sunzen Group Berhad Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sunzen Group Berhad.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth	18.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) CEO Looks Due For A Compensation Raise

Dec 12

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Nov 07

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

Oct 15

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sunzen Group Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KLSE:SUNZEN - Analysts future estimates and past financials data (MYR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	95	6	9	10	N/A
12/31/2023	98	7	9	9	N/A
9/30/2023	86	5	0	1	N/A
6/30/2023	84	4	-9	-8	N/A
3/31/2023	92	4	-16	-14	N/A
12/31/2022	97	4	-34	-32	N/A
9/30/2022	109	3	-22	-21	N/A
6/30/2022	103	2	-32	-30	N/A
3/31/2022	95	2	-44	-42	N/A
12/31/2021	90	1	-19	-16	N/A
9/30/2021	89	-9	-16	-14	N/A
6/30/2021	92	-9	3	5	N/A
3/31/2021	85	-11	19	21	N/A
12/31/2020	82	-13	6	7	N/A
9/30/2020	99	-17	-8	-6	N/A
6/30/2020	141	-20	-8	-6	N/A
3/31/2020	195	-20	-12	-8	N/A
12/31/2019	241	-18	-15	-11	N/A
9/30/2019	270	-13	-6	-3	N/A
6/30/2019	307	-11	-14	-11	N/A
3/31/2019	292	-8	-16	-14	N/A
12/31/2018	296	-7	-6	-4	N/A
9/30/2018	325	1	-19	-16	N/A
6/30/2018	304	3	-5	-2	N/A
3/31/2018	329	2	N/A	0	N/A
12/31/2017	303	3	N/A	4	N/A
9/30/2017	214	6	N/A	15	N/A
6/30/2017	144	4	N/A	13	N/A
3/31/2017	78	2	N/A	15	N/A
12/31/2016	40	0	N/A	0	N/A
9/30/2016	35	-3	N/A	0	N/A
6/30/2016	33	-3	N/A	-9	N/A
3/31/2016	32	-2	N/A	-10	N/A
12/31/2015	32	0	N/A	-5	N/A
9/30/2015	34	1	N/A	-2	N/A
6/30/2015	36	1	N/A	3	N/A
3/31/2015	37	1	N/A	2	N/A
12/31/2014	37	1	N/A	4	N/A
9/30/2014	38	2	N/A	3	N/A
6/30/2014	39	3	N/A	2	N/A
3/31/2014	38	3	N/A	2	N/A
12/31/2013	37	4	N/A	2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SUNZEN's forecast earnings growth is above the savings rate (3.6%).

Earnings vs Market: Insufficient data to determine if SUNZEN's earnings are forecast to grow faster than the MY market

High Growth Earnings: Insufficient data to determine if SUNZEN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SUNZEN's revenue is forecast to grow faster than the MY market.

High Growth Revenue: Insufficient data to determine if SUNZEN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SUNZEN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 07:12
End of Day Share Price	2024/12/26 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunzen Group Berhad is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Sunzen Group Berhad Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) CEO Looks Due For A Compensation Raise

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

New major risk - Shareholder dilution

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20